Skip to main content
. Author manuscript; available in PMC: 2017 Jul 11.
Published in final edited form as: Semin Immunol. 2011 Dec 1;24(2):96–108. doi: 10.1016/j.smim.2011.08.022

Fig. 3.

Fig. 3

Serum alloantibody production and chronic rejection development in alemtuzumab treated CD52Tg mice. (A) Elevated alloantibody production at 10 weeks post transplantation with CR-developed recipients (*p < 0.05). (B) Histologic and immunohistochemical eveidence of antibody-mediated chronic rejection. Slides prepared of post-transplant day 100 cardiac allograft with Elastic, trichrome, and C4d. (a) Elastic staining shows increased neo-intimal hyperplasia in the coronary artery. (b) Trichrome staining reveals higher pathological grades in fibrosis indicated in blue. (c) Immunoperoxidase demonstrates diffuse deposits of C4d (dark brown) in the capillary and arterial endothelium (inset) in a section from a cardiac allograft from C57BL/6 to CD52Tg recipient with alemtuzumab treatment at day 100.